Evaluation of The Awareness of Medical Practitioners About Drug-Induced Gingival Enlargement: A Preliminary Study
Abstract
Objective: Gingival enlargement is a clinical condition characterized by hyperplasia and hypertrophy, which has an etiology of inflammation originating from dental plaque, hormones, genetics, malignant or benign lesions, and drugs. The drugs causing gingival enlargement include anti-convulsants, calcium channel blockers, immunosuppressants, and high-dose oral contraceptives. This study aimed to investigate the awareness of specialist and practitioner medical doctors about the drugs causing gingival enlargement.
Material and Methods: A total of 100 respondents participated in this questionnaire study. A self-reported questionnaire was formed to evaluate the awareness of the study participants about drugs causing gingival enlargement. The questionnaire was prepared online using Google forms and was introduced and distributed on the social networks of Facebook and WhatsApp.
Results: % 27 of the respondents reported that anti-convulsants caused gingival enlargement, followed by immunosuppressants at the rate of 23%, calcium channel blockers at 19%, and oral contraceptives at 11%. Although there is no consensus in the literature that antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs) cause gingival enlargement, 9.2% of the study respondents reported that antibiotics caused gingival enlargement, 4.3% NSAIDs, and 5.4% antidepressants.
Conclusion: In studies evaluating the awareness of healthcare personnel about drug adverse effects, it has been shown that personnel have knowledge on this subject, but do not report this at a sufficient level. The results of this study suggest that specialist and practitioner medical doctors had insufficient awareness about drugs causing gingival enlargement.
Keywords
anti-convulsants, calcium channel blockers, gingival enlargement, immunosuppressives, high-dose oral contraceptives
Supporting Institution
Destek alınmamıştır.
Project Number
yok
Ethical Statement
Approval for this study, which was conducted between March 2021 and October 2021, was granted by the Non-Interventional Clinical Research Ethics Committee (decision no:01, session no:2021/06).
References
- Beaumont J, Chesterman J, Kellett M, Durey K. Gingival overgrowth: Part 1: aetiology and clinical diagnosis. British dental journal.2017; 222(2): 85-91.
- Murakami S, Mealey BL, Mariotti A, Chapple ILC. Dental plaque-induced gingival conditions [Internet]. Journal of periodontology. 2018;89:17–27.
- Angelopoulos AP, Goaz PW. Incidence of diphenylhydantoin gingival hyperplasia. Oral Surgery, Oral Med Oral Pathol. 1972;34:898–906.
- Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason JM. Prevalence of Gingival Overgrowth Induced by Calcium Channel Blockers: A Community-Based Study. J Periodontol. 1999;70:63–67.
- Hassell TM, Hefti AF. Drug-Induced Gingival Overgrowth: Old Problem, New Problem. Vol. 2, Critical Reviews in Oral Biology and Medicine. 1991;103-137.
- T Al-Saffar M. The Effects of Contraceptive Pills on Oral Health: A Review Study. Acta Sci Dent Scienecs . 2019;3:61–64.
- Seymour RA, Ellis JS, Thomason JM. Risk factors for drug-induced gingival overgrowth. J Clin Periodontol 2000;27:217–23.
- Chesterman J, Beaumont J, Kellett M, Durey K. Gingival overgrowth: Part 2: management strategies. Nat Publ Gr 2017;159-65.
- Pavlic V, Zubovic N, Ilic S, Adamovic T. Untypical Amlodipine-Induced Gingival Hyperplasia. Case Reports in Dentistry 2015;1-4
- Prakah R, Mohan S, Rastogi K, Bhushan R, Verma S. Phenytoin-induced gingival enlargement: a dental awakening for patients with epilepsy. Case Reports. 2013; bcr2013008679.